Analysts/Institutional Investor Meet/Con. Call Updates

November 1, 2026 BSE Limited National Stock Exchange of India Limited Department of Corporate Services Listing Department, Floor 25, Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Kala Ghoda, Fort Bandra Kurla Complex, Bandra (East), Mumbai - 400 001 Mumbai – 400 051 Scrip Code No: 542665 Company Symbol: NEOGEN Debt Segment Code: 977028 Sub.: Earnings Presentation on the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/ Madam, With reference to the captioned subject, please find enclosed herewith the Earnings Presentation on the unaudited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30, 2026. The Earnings Presentation is also being uploaded on the Company’s website at https://neogenchem.com/financial-performance/. Kindly take the same on your record. Thanking you, For Neogen Chemicals Limited Unnati Kanani Company Secretary and Compliance Officer Mem. No.: A35131 Encl.: As above Registered Office: 1002, Dev Corpora, Cadbury Junction, E: investor@neogenchem.com T: +91 22 2549 7300 Eastern Express Highway, Thane (W) 400 601, India. W: www.neogenchem.com F: +91 22 2549 7399 CIN No. L24200MH1989PLC050919 Delivering Performance Sustaining Trust Creating Value Q2 FY27 Earnings Presentation November 2026 Safe Harbor Certain statements in this document may be forward-looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Neogen Chemicals Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances. Table of Contents 01 02 03 04 05 06 Q2 FY27 Introduction to Industry Overview: Way Sustainability & Contact Us Financial Neogen Chemicals Lithium-Ion Batteries Forward CSR Initiatives Performance & Expansion Initiatives Q2 FY27 Financial Performance & Expansion Initiatives Performance Highlights – Q2 FY27 Q2 FY27 Revenue break-up** INR in crore Standalone Consolidated Revenues 39% | 288 42% | 296* Domestic *Exports Gross Profit 27% | 121 36% | 133 *Including deemed exports EBITDA 54% | 54 51% | 45 PAT 127% | 21 144% | 8 Organic Inorganic **Consolidated figures * Consolidated Revenues include INR 37 crore from Battery Chemicals Note: Growth for Q2 FY27 is compared to Q2 FY26 55 Financial Summary – Q2 FY27 REVENUE ● Delivered robust growth, navigating Middle East geopolitical conflicts, supply chain Standalone Consolidated friction, and feedstock cost inflation INR in crore ● Led by sustained volume improvement in core segments, anchored by 288 296 Organolithium's expansion into high-growth emerging applications 207 209 ● Accelerated scaling in the Battery Chemicals division, Neogen Ionics (NIL), with Q2 FY27 revenue surging to INR 37 crore (vs. INR 5.4 crore in Q2 FY26) Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 EBITDA ● Achieved strong EBITDA performance despite higher cost base related to Dahej plant Standalone Consolidated rebuild, tolling arrangements, NIL capital expenditure, and elevated input costs INR in crore 54 ● Consolidated EBITDA reflects the initial fixed-cost absorption at NIL, while revenue 35 scale-up and capacity utilization are still ramping up, setting the foundation for future operating leverage ● Standalone EBITDA Margin for Q2 FY27 – 18.6% Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 ● PAT reflected core operational performance, impacted temporarily by higher interest Standalone Consolidated and depreciation costs from ongoing CAPEX initiatives INR in crore 8 ● Interest expenses are expected to decline moving ahead, supported by term debt reduction using QIP proceeds and lower borrowing costs following credit rating upgrade Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Revenue break-up – Q2 & H1 FY27 (consolidated) Organic Chemicals Inorganic Chemicals Battery Chemicals 238 37 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 114 56 H1 FY26 H1 FY27 H1 FY26 H1 FY27 H1 FY26 H1 FY27 Financial Table – Profit & Loss Statement (Standalone) Particulars (INR In crore) Q2 FY27 Q2 FY26 Growth (%) H1 FY27 H1 FY26 Growth (%) Revenue 288.0 206.7 39% 540.3 391.3 38% Expenditure 234.3 171.7 36% 438.4 321.6 36% EBITDA 53.7 35.0 54% 101.9 69.6 46% EBITDA Margins 18.6% 16.9% +174 bps 18.9% 17.8% +105 bps Depreciation 7.0 6.4 10% 13.8 11.3 23% Other Income 8.3 4.4 89% 16.2 7.7 111% EBIT (inc. Other Income) 55.0 32.9 67% 104.2 66.0 58% Interest 26.6 20.6 29% 49.7 34.6 43% Profit Before Tax 28.4 12.3 131% 54.6 31.4 74% PBT Margins 9.9% 6.0% +391 bps 10.1% 8.0% +207 bps Exceptional Items 0.0 0.0 NA 0.0 0.0 NA Profit Before Tax (inc. exceptional 28.4 12.3 131% 54.6 31.4 74% items) Tax Expense 7.3 3.0 141% 14.0 7.9 78% Profit After Tax 21.1 9.3 127% 40.6 23.6 72% PAT Margins 7.3% 4.5% +284 bps 7.5% 6.0% +149 bps Earnings Per Share (INR) 7.60 3.53 115% 14.75 8.93 65% * Not annualized 8 Financial Table – Profit & Loss Statement (Consolidated) Particulars (INR In crore) Q2 FY27 Q2 FY26 Growth (%) H1 FY27 H1 FY26 Growth (%) Revenue 296.0 208.7 42% 546.3 395.4 38% Expenditure 250.6 178.7 40% 452.7 333.9 36% EBITDA 45.3 30.0 51% 93.6 61.5 52% EBITDA Margins 15.3% 14.4% +95 bps 17.1% 15.5% +158 bps Depreciation 8.8 7.3 20% 17.0 13.1 30% Other Income 4.0 1.9 110% 7.8 3.1 155% EBIT (inc. Other Income) 40.5 24.5 65% 84.4 51.5 64% Interest 27.8 19.5 43% 48.6 32.1 51% Profit Before Tax 12.7 5.2 147% 36.0 19.5 85% PBT Margins 4.3% 2.5% +183 bps 6.6% 4.9% +167 bps Exceptional Items 0.0 0.0 NA 0.0 0.0 NA Profit Before Tax (inc. exceptional 12.7 5.2 147% 36.0 19.5 85% items) Tax Expense 4.5 1.8 152% 10.7 5.8 84% Profit After Tax 8.2 3.4 144% 25.3 13.7 86% PAT Margins 2.8% 1.6% +117 bps 4.6% 3.5% +119 bps Earnings Per Share (INR) 2.96 1.28 131% 9.21 5.18 78% * Not annualized 9 Balance Sheet Snapshot (Consolidated) Particulars (INR In crore) Sep 30, 2026 Sep 30, 2025 Assets Non-Current Assets 2,004 983 Current Assets 2,001 1,319 • Standalone: Total Debt at INR 750 crore in H1 FY27; Net Debt at INR 378 crore Total Assets 4,005 2,302 • Consolidated: Total Debt at INR 1,560 crore in H1 FY27; Net Debt at INR 1,095 crore Liabilities Shareholders’ Funds 1,578 800 • Liquid investments (including Fixed Deposits): INR 465 crore as on 30th Sept 2026 Non-Current Liabilities 944 665 Current Liabilities 1,484 837 Total Liabilities & Equity 4,005 2,302 Expansion of Organolithium manufacturing facility • The board has approved expansion of Organolithium facility at Patancheru, Telangana from 300 MTPA to 600 MTPA with proposed estimated investment of upto INR 45 crore with additional revenue potential of INR 150 to INR 200 crore based on lithium prices Insurance Claim Status Key • Cumulative recoveries stand at INR 164 crore to date, comprising INR 155 crore in on- account insurance claims (including a recent tranche of INR 15 crore in July 2026) and INR 9 crore from salvage realization. Also incurred further incidental charges of INR 1 crore which Updates is claimed as per insurance policy • On Oct 29, 2026, the Company accepted an additional claim amount of Rs. 152 crore from Q2 FY27 the insurance company, to be released in due course as part-payment of the total receivable • Total on-account claim received/ receivable stands at Rs. 316 crore, inclusive of above (Neogen accepted claim and salvage scrap sales to date. Chemicals) Fund Raise • Raised INR 600 crore via first-ever QIP; Issue Oversubscribed by 6.5x • QIP attracted strong participation from a diverse mix of renowned domestic and global institutional investors • Proceeds utilized towards debt repayment, fund incremental busines [Showing first 8,000 characters — download PDF for full document]